Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Hydra Biosciences, Inc.

Other

Novartis Ag

Daiichi Pharmaceutical Co., Ltd.

Pharmacopeia Drug Discovery, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Christopher Ronald Sarko

Michael Dennis Lowe

Hossein Razavi

Michael Robert Turner

Thierry Bouyssou

Xinyuan Edward Wu

Lana Louise Smith Keenan

Simon Surprenant

Niklas Heine

Neil Moss

Hidenori Takahashi

Dirk Gottschling

Zhonghua Zhang

John David Ginn

John J Baldwin

Daniel R Goldberg

Atsushi Nakayama

Edward McDonald

Thomas Martin Kirrane, Jr

Roger John Snow

Abdelhakim Hammach

Alan David Swinamer

Donghong Amy Gao

Can Mao

Pingrong Liu

Norbert Hauel

Sanjaya Singh

David S Thomson

John David Huber

Ming-Hong Hao

Daniel Kuzmich

Derek Cogan

Keith Allen Canada

Charles Lawrence Cywin

Heather Tye

Thomas Wai-Ho Lee

Mark Whittaker

Benjamin R Taft

Zhaoming Xiong

Yunlong Zhang

Nicole Blaquiere

Pui Leng Loke

Brian Nicholas Cook

Qiang Zhang

Maolin Yu

Alisa K Waterman

Steven Richard Brunette

Fumiaki Yokokawa

John Lord

Jehrod Burnett Brenneman

Gregory Paul Roth

Fariba Soleymanzadeh

Kevin Joseph Moriarty

Nobuo Machinaga

Jun Chiba

Yoshiyuki Yoneda

Brian Christopher Raudenbush

Xin Guo

Wang Mao

Shin Iimura

Darren DiSalvo

Tobias Litzenburger

Victor Marc Kamhi

Darren Todd Disalvo

Edward S Tasber

Kevin Chungeng Qian

Andreas Kordikowski

Tingying Zhu

Mark Stephen Ralph

John A Westbrook

Christian Harcken

Robert Copenhaver

Joanne Van Ryn

Jianwen Cui

Stephen James Boyer

Antonio J Barbosa

Steven S Pullen

Tamara Denise Hopkins

Antonio Jose Del Moral Barbosa, Jr

Thomas Wei-Ho Lee

Jord Lord

Alen David Swinamer

Iimura Shin

Andre White

Paul Nicklin

Richard Yichong Huang

Anne-Catherine Mata

Grace Lamprecht Waldron

Noel Stewart Wilson

Jinbo Lee

Samantha Jayne Bamford

Michael D Lowe

Steven Brunette

The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Inhibitors of TRPC6

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; 

Compounds and compositions for the treatment of parasitic diseases

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein Rto R, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Alkoxy pyrazoles as soluble guanylate cyclase activators

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

Heterocyclic compounds containing an indole core

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof

Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds. 

Serotonin 5-HT2B receptor inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, A and B are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Soluble guanylate cyclase activators

Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Pyrazole compounds as CCR1 antagonists

Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Indazole compounds as CCR1 receptor antagonists

Disclosed are amide compounds of formula (I): wherein Ar, Q, Y and R-Rof formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases

Growing community of inventors

New Milford, CT, United States of America

Christopher Ronald Sarko